The pharmaceutical company GSK earns 7% more until June and improves annual forecasts

MADRID, 27 Jul. (EUROPA PRESS) -

The British laboratory GlaxoSmithKline (GSK) closed the first half of 2022 with an attributed net profit of 2,640 million pounds (3,124 million euros), which represents an increase of 7% compared to the same period of 2021, as follows of the income statement that the company published this Wednesday.

Revenues up to June rose 28.4% and stood at 14,119 million pounds (16,709 million euros). By business segments, the specialized medicine division grew by 69%, to 5,839 million (6,910 million euros), while the general medicine division stood at 4,896 million pounds (5,794 million euros), 3% more.

On its side, the vaccine branch experienced a 21% increase in turnover, up to 3,384 million pounds (4,005 million euros).

Between April and June, GSK's profits decreased by 40%, to 838 million pounds (992 million euros), while turnover increased by 18.7%, to 6,929 million pounds (8,200 million euros). .

"We delivered an excellent performance in the second quarter, with strong growth in specialty medicines, including HIV, and a record quarter for our shingles vaccine, Shingrix," said Emma Walmsley, CEO of GSK.

"With this momentum in sales and operating profit growth, we have raised our guidance for the full year and are confident of meeting the long-term growth prospects we set out for shareholders last year," he added.

In this way, the laboratory now expects an increase in sales in 2022 of between 6% and 8%, compared to the previous range of 5% to 7%, as well as a growth in adjusted operating income of between 13%. and 15%, above the range of 12% to 14% previously anticipated.